The AKT inhibitors pipeline has more than 15 drugs. In pipeline analysis, drugs are analyzed based on route of administration and molecule type. The pipeline is also analyzed on the basis of monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-clinical stage.
Phase III & Filed
Phase III clinical trial known for the comparison of new treatments with the standard treatment in which the safety, efficacy and side effects of new intervention is compared with the already existing treatment. The Phase III clinical trial takes around 2-3 years to complete and the total number of participants vary from 100-1,000. After the completion of Phase III stage, the company files New Drug Application (NDA) to the regulatory authorities known as filed stage. There is no AKT inhibitor drug in Phase III clinical trial and one drug is in filed stage. Novartis AG has filed NDA in U.S. for midostaurin, for the treatment of FLT3-mutated acute myeloid leukemia. The marketing authorization application has already been accepted by the European Medicines Agency for midostaurin for the treatment of FLT3-mutated acute myeloid leukemia.
Rexahn Pharmaceuticals, Inc. has developed Archexin, a phase II drug candidate for the treatment of renal cell carcinoma. Phase II clinical trial is the second phase that answer safety, efficacy and dosing of the new intervention. There are total 8 drugs present in phase II trial of AKT inhibitors. Phase II clinical trial take around 2 years to complete and between 100 – 120 patients participate in the Phase II trial.
Triciribine phosphate (PTX 200), a drug candidate of Prescient Therapeutics Ltd., is in phase I stage of development for the treatment of acute myeloid leukemia, recurrent or persistent platinum resistant ovarian cancer, breast cancer, lung cancer and esophageal cancer. There are 4 drugs present in Phase I clinical stage. In Phase I clinical trial, safety of the new intervention is determined. The trial takes around 1-2 years to complete and the total number of volunteers participating in the trial vary between 15 – 30.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/akt-protein-kinase-b-inhibitors-pipeline-analysis/toc-sample
ASN003, a drug candidate of Asana BioSciences, LLC, is in preclinical stage of development for the treatment of melanoma and colon cancer. There are 2 AKT inhibitor drugs present in preclinical trial. Preclinical study is also known as animal study. It is done before testing a drug in people to find out the toxicity profile of the drug. Preclinical study is of two types, including In vitro and In vivo.
Pipeline analysis provides description about the key companies which are developing AKT inhibitor drugs. Some of the key players actively involved in the research and development are AstraZeneca plc, Cellectar Biosciences Inc., GlaxoSmithKline plc, Novartis AG, Prescient Therapeutics Ltd and Asana BioSciences, LLC.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)